Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · March 20, 2023

Adjuvant Nivolumab Plus Ipilimumab vs Placebo for Localised Renal Cell Carcinoma After Nephrectomy

The Lancet


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial
Lancet 2023 Feb 09;[EPub Ahead of Print], RJ Motzer, P Russo, V Grünwald, Y Tomita, B Zurawski, O Parikh, S Buti, P Barthélémy, JC Goh, D Ye, A Lingua, JB Lattouf, L Albigès, S George, B Shuch, J Sosman, M Staehler, S Vázquez Estévez, B Simsek, J Spiridigliozzi, A Chudnovsky, A Bex

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading